On April 17, Ge Longhui Pharmaceutical (688073.SH) said on the investor interactive platform that Bide Pharmaceutical's main business is to provide customers with products or services related to “molecular blocks and scientific research reagents”. Currently, the company's cooperation with Huawei is still small. If the amount of subsequent orders meet the disclosure standards, it will fulfill its obligation to disclose information. The field of new materials has very good potential for development, and the company has always kept a close eye on it.
毕得医药(688073.SH)：目前与华为合作体量尚小
Bide Pharmaceutical (688073.SH): Currently, the cooperation with Huawei is still small
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.